RxDoctor Payments Data

Bruce Andrea, MD

Cardiovascular Disease · Durango, CONPI 1609841949

Payments from drug & device makers

$1,573in general payments, 2019–2025

Across 79 payments — averaging $19.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$540
  • Amgen$183
  • W. L. Gore & Associates, Inc.$135
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$102
  • AstraZeneca$92
  • Sanofi-aventis U.S. LLC$91
  • plus $431 from 9 others

What the payments were for

  • Food & beverage$1,573100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,573 in reported general payments places this provider in the 45th percentile of 276 cardiovascular disease providers in Colorado.

See all cardiovascular disease providers in Colorado

Medicare billing

Part B allowed, 2024
$190,045
Medicare patients
418
Services billed
2,615

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban301$448,421
OpsumitMacitentan19$232,241
EntrestoSacubitril/Valsartan51$77,426
XareltoRivaroxaban57$75,956
Repatha SureclickEvolocumab64$60,676
Praluent PenAlirocumab20$27,322
OzempicSemaglutide21$26,262
JardianceEmpagliflozin15$25,197
Candesartan Cilexetil99$12,531
Metoprolol Succinate517$8,159
Ranolazine ErRanolazine45$7,199
Flecainide Acetate114$6,467
Ezetimibe174$5,734
Atorvastatin Calcium384$3,785
Nebivolol Hcl51$3,470

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$23$448,421301 claims
NovartisEntresto$57$77,42651 claims
Johnson & JohnsonXarelto$78$75,95657 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 276 cardiovascular disease providers in Colorado.

Other cardiovascular disease in Durango

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →